Age-related macular degeneration (“AMD”) represents a large unmet medical need with estimates of 2 million patients and another 7 million people at risk in the U.S. alone. Approximately, 85-90% of the AMD patients have the “dry” form of the disease.
There are no approved treatments for dry AMD.
The emotional and socioeconomic impact of AMD is large because of the reading and driving impairment caused by the disease, which primarily affects central (straight-on) rather than peripheral (side) vision.
Emerging clinical data highlight an exciting new opportunity to improve visual acuity in the elderly with age-related macular degeneration (AMD) with photobiomodulation (PBM). The Company is developing an ophthalmologic office-based LED instrument for commercial use as non-invasive medical treatments.
As the population continues to age, degenerative ocular diseases become increasingly common and create additional burden on the health care system.
It is predicted that AMD will become a more prevalent cause of blindness than both diabetic retinopathy and glaucoma combined.